Agreed, with mid-November Q2 fiscal results release and hopefully generic OxyContin news around time of antimetabolite approval. Will be good next 6 months. I’m eager to hear how R&D pipeline is getting replenished, upcoming filings (excl gen Vyvanse). I expect generic Concerta to be on deck for bioequivalency w/ filing 1H 2024. After this is filed, we don’t have ton of insight into next big opportunities.